Pharmaceutical contract development and manufacturing organisation (CDMO) SGS Quay Pharma has been recognised with a Queen’s Award in the UK for the strength of its export sales.
The CDMO won a Queen’s Award for Enterprise in the category of International Trade and was recognised for the strength of its export sales which since 2010 have made up over 55% of its business. In the last three years, SGS Quay Pharma has more than doubled its overseas sales.
The award was presented by the Lord Lieutenant of Clwyd, Henry Fetherstonhaugh, OBE, in a special ceremony at the company’s global headquarters in Deeside Industrial Park, Flintshire.
SGS Quay Pharma has expanded internationally with a sales office and development manufacturing facility in the US. The company is also targeting new markets including Belgium, Denmark, Germany, Spain, Iceland, South Korea and Australia.
SGS Quay Pharma puts its success down to its work in live biotherapeutics, which focus on the use of microbes to illicit a pharmaceutical response, specifically targeted at the immune system.
The company has continued to invest to support its ongoing expansion. As well as the establishment of its US operation, this has included the opening of a second 22,500 sq ft laboratory and office facility, close to its headquarters in Deeside Industrial Park, alongside the creation of specialised manufacturing spaces and the purchase of specialist equipment to support and expand its range of services.
“We were delighted to welcome the Lord Lieutenant to our headquarters and to be able to share this important award with our team, who have all been critical to our achieving this honour,” said SGS Quay Pharma’s Commercial Operations Director Maireadh Pedersen.
“This is an exciting time for pharmaceutical outsourcing, and we have ambitious plans to continue to develop our global business. The Queen’s Award provides the ideal foundation for the next phase of our growth.”